Coherus Oncology：催化剂密集的时期已经到来 (NASDAQ:CHRS)
· seekingalpha.com
CHRS 正面临 2026 年下半年至 2027 年上半年的关键催化剂，包括 tagmokitug/casdozokitug 的数据解读、Loqtorzi 销量的增长，以及 CCR8 数据的潜在上行空间。点击此处阅读详情。
Coherus Oncology ( CHRS ) has not experienced a sustained run-up, despite the fact the company is approaching a catalyst-rich period. Given CHRS had five or mor...